Caitong Securities(SH:601108) 智通财经网·2025-08-11 06:29Core Insights - Gout is a significant health issue in China, with over 30% of the world's gout patients residing in the country, projected to reach nearly 18 million by 2025 [1] Group 1: Gout Prevalence and Treatment - China accounts for 17.4% of the global population but has over 30% of the world's gout patients, indicating a high prevalence of the disease [1] - The prevalence of hyperuricemia among Chinese adults reached 14% according to 2018-2019 data, with some progressing to gout [1] Group 2: Treatment Approaches - Gout treatment is divided into acute phase relief and chronic uric acid lowering therapy, with first-line medications including colchicine and NSAIDs for acute treatment [2] - Common medications for uric acid lowering include xanthine oxidase inhibitors (allopurinol, febuxostat), uricosuric agents (benzbromarone, probenecid), and uricase agents (pegloticase, rasburicase) [2] Group 3: Research and Development in Uric Acid Lowering - Research on uric acid lowering treatments is focused on URAT1 inhibitors, with drugs like Molnupiravir showing promising efficacy and safety, potentially becoming first-line treatments [3] - The competition in the URAT1 inhibitor space remains intense, with several candidates still awaiting further clinical efficacy data [3] Group 4: Acute Phase Relief Innovations - Research for acute phase relief is centered on IL-1β inhibitors, with the approval of Vusirikumab, the first IL-1β inhibitor in China, which significantly reduces the risk of recurrence by over 90% [4] - Vusirikumab's pain relief efficacy is comparable to that of combination betamethasone, marking a significant advancement in gout treatment [4]